Intraoperative neurophysiological monitoring

WISE Receives FDA Clearance for its WISE Cortical Strip Bringing Neuromonitoring to the Next Level

Retrieved on: 
Thursday, December 1, 2022
Semiconductor, Manufacturing, Biometrics, Nanotechnology, Other Science, Research, Medical Devices, Hardware, Hospitals, Science, Technology, FDA, Biotechnology, Neurology, Surgery, Public Relations, Investor Relations, Health, Communications, Engineering, Electrode, Intra, University, SCS, Multimedia, EUREKA, Spinal cord, Safety, WIN, Brain, Modulation, Clinical neurophysiology, Neurosurgery, Intraoperative neurophysiological monitoring, University of Milan, WISE, BMI, CE, New Frontier, Hyperreflexia, FDA, Medical device, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20221201005070/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221201005070/en/
    The WISE Cortical Strip is the first product receiving FDA clearance within the Companys WISEneuro Monitoring product family.
  • The FDA clearance follows the CE mark already received by the product in May 2021.
  • The WISE Cortical Strip performances have been successfully validated in a multicentric pre-market clinical study in Europe, the WIN study ( NCT03731455 ), that demonstrated safety, performance and usability of the product.
  • As a result, the WISE Cortical Strip is highly ergonomic and conformable to the brain surface.

Assure Holdings Further Strengthens Clinical Team with Hiring of James Watt as National Technologist Director

Retrieved on: 
Tuesday, April 26, 2022
News, Annual report, CEO, Society, Intraoperative neurophysiological monitoring, Joint Commission, Spring Arbor University, Deep brain stimulation, EEG, COVID-19, Nose, NASDAQ, U.S. Securities and Exchange Commission, Hospital, Organization, GLOBE, Education, Spine, Form 10-K, Surgeon, Biotronik, CSET, Company, CNIM, Forward-looking statement, NuVasive, ASET, Neurosurgery, Â, Certification, Nervous system, DBS, Central Society, Risk, Physician, SSET, Ear, Management, Risk management, Biology, Science

DENVER, April 26, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (IONM) and remote neurology services, announced the appointment of James Watt to the position of national technologist director.

Key Points: 
  • DENVER, April 26, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (IONM) and remote neurology services, announced the appointment of James Watt to the position of national technologist director.
  • Mr. Watt reports to Assures vice president of clinical operations, Stephanie Krouse.
  • In his new role, Mr. Watt leads day-to-day operations for Assures clinical technologist team, ensuring quality of service and overseeing the Companys training and development program.
  • Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients neural structures throughout the procedure communicating in real-time with the surgeon and technologist.

Assure Holdings Performs First Neuromonitoring Case in Nebraska

Retrieved on: 
Thursday, July 29, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Branches of biology

DENVER, July 29, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it has performed its first neuromonitoring case in the state of Nebraska.

Key Points: 
  • DENVER, July 29, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it has performed its first neuromonitoring case in the state of Nebraska.
  • Assure is continuing to generate strong organic growth, both by expanding into new states and extending our reach within our current operational footprint.
  • Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commissions Gold Seal of Approval.

Assure Sets Monthly Record for Cash Collection and Procedures in June 2021

Retrieved on: 
Tuesday, July 6, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, OTC Markets Group, Branches of biology

DENVER, July 06, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced a monthly record for cash collection and number of procedures during June 2021.

Key Points: 
  • DENVER, July 06, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced a monthly record for cash collection and number of procedures during June 2021.
  • Results and expectations relating to billing and collections include:
    The Company collected a monthly record $2.7 million in June 2021.
  • Based upon recent discussions with various insurance providers, Assure expects to continue the strong trend of collections in 2021.
  • Farlinger concluded, The Company reported more than 1,600 cases in June 2021, our highest number of monthly procedures ever.

NuVasive Receives Latest CE Mark Approval for Pulse Platform and Starts Global Clinical Evaluations

Retrieved on: 
Wednesday, June 30, 2021
Medicine, Branches of biology, Clinical medicine, NuVasive, Anesthesia, Intraoperative neurophysiological monitoring, Pulse

"The latest CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform and further our plan for an expanded global launch later this summer," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.

Key Points: 
  • "The latest CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform and further our plan for an expanded global launch later this summer," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.
  • Pulse is a first-of-its-kind technology that integrates radiation reduction,1 imaging enhancement, rod bending, navigation, intraoperative neuromonitoring, and spinal alignment tools into a single platform.
  • Pulse is designed to increase safety, efficiency, and procedural reproducibility, while addressing some of the most common clinical challenges in spine surgery.
  • I am impressed by the results I am experiencing with Pulse and look forward to continue using this innovative platform in the OR."

NuVasive Receives Latest CE Mark Approval for Pulse Platform and Starts Global Clinical Evaluations

Retrieved on: 
Wednesday, June 30, 2021
NuVasive, Clinical medicine, Anesthesia, Intraoperative neurophysiological monitoring, Pulse, Branches of biology

"The latest CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform and further our plan for an expanded global launch later this summer," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.

Key Points: 
  • "The latest CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform and further our plan for an expanded global launch later this summer," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.
  • Pulse is a first-of-its-kind technology that integrates radiation reduction,1 imaging enhancement, rod bending, navigation, intraoperative neuromonitoring, and spinal alignment tools into a single platform.
  • Pulse is designed to increase safety, efficiency, and procedural reproducibility, while addressing some of the most common clinical challenges in spine surgery.
  • 2The Pulse platform can be used in every procedure; however, not all modalities are cleared for every procedure.

Assure Holdings Supports Rare Auditory Brainstem Implant Surgery

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Medicine, Clinical medicine, Electroencephalography, Prosthetics, Anesthesia, Electrodiagnosis, Intraoperative neurophysiological monitoring, Medical monitoring, Auditory brainstem implant, Brainstem, Implant

DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it supported a successful auditory brainstem implant surgery.

Key Points: 
  • DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it supported a successful auditory brainstem implant surgery.
  • The auditory brainstem implant surgery was performed to restore hearing in a patient who had lost this function.
  • In addition, neurophysiologists monitored all associated lower cranial nerves, minimizing the potential negative side effects of the implant.
  • Assure Neuromonitoring was a critical part of the team allowing us to successfully complete the auditory brainstem implant procedure, said Dr. Moises Arriaga.

Assure Reports a Record Number of Monthly Procedures in May 2021

Retrieved on: 
Wednesday, June 16, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Neurology, OTC Markets Group, Branches of biology

DENVER, June 16, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced its highest ever number of monthly procedures during May 2021.

Key Points: 
  • DENVER, June 16, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced its highest ever number of monthly procedures during May 2021.
  • The Company reported our highest number of monthly procedures in May, managing over 1,400 cases, said John A. Farlinger, Assures executive chairman and CEO.
  • In addition, Assures monthly procedure total benefitted from the Companys launch of professional neurology services for IONM which boosted our number of cases performed.
  • Assure has appointed Jerod Powell to the newly created chief information officer (CIO) position.

Assure to Attend Investor Conferences in June 2021

Retrieved on: 
Thursday, May 27, 2021
Finance, Money, Economy, OTC Markets Group, Intraoperative neurophysiological monitoring, Webcast, Investor

DENVER, May 27, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences in June 2021:

Key Points: 
  • DENVER, May 27, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences in June 2021:
    MicroCap Rodeo Summer Solstice Conference June 1-4, 2021.
  • Register for the webcast here: https://www.webcaster4.com/Webcast/Page/2134/41510
    Adelaide Capital Investor Update Webinar June 2, 2021.
  • The webinar will facilitate the introduction of Assure to a curated group of mainly Canadian retail investors, investment advisors, portfolio managers, and other finance industry professionals.
  • Register to attend the webcast free here: https://ldmicrojune2021.mysequire.com/
    The Life Sciences Investor Forum on June 24, 2021.

WISE’s Cutting-Edge Cortical Neuromonitoring Electrode Receives CE Mark

Retrieved on: 
Tuesday, May 18, 2021
Biotechnology, Health, Medical devices, Branches of biology, Neuroscience, Neurophysiology, Neurotechnology, Electrodiagnosis, Neuromodulation, Neuropsychology, Pain, Intraoperative neurophysiological monitoring, XC2

b'WISE Srl, a medical device company developing next-generation implantable electrodes for neuromonitoring, neuromodulation and brain-machine interfacing (BMI), today announced the CE marking of its WISE Cortical Strip (WCS\xc2\xae), a single use medical device intended to be used on the surface of the brain for intraoperative neurophysiological monitoring (IONM).\nThe WISE Cortical Strip is the first product receiving CE mark within the Company\xe2\x80\x99s WISEneuro\xc2\xae Monitoring product family.

Key Points: 
  • b'WISE Srl, a medical device company developing next-generation implantable electrodes for neuromonitoring, neuromodulation and brain-machine interfacing (BMI), today announced the CE marking of its WISE Cortical Strip (WCS\xc2\xae), a single use medical device intended to be used on the surface of the brain for intraoperative neurophysiological monitoring (IONM).\nThe WISE Cortical Strip is the first product receiving CE mark within the Company\xe2\x80\x99s WISEneuro\xc2\xae Monitoring product family.
  • The CE mark follows the successful conclusion of the WIN study, a multicentric pre-market clinical study that demonstrated safety, performance and usability of WISE\xe2\x80\x99s device ( NCT03731455 ).
  • Unlike traditional cortical electrodes, which are made of stiff metal discs enclosed in a thick silicone foil, the WISE Cortical Strip is composed of stretchable platinum contacts embedded in a soft and thin film of silicone.
  • In addition to neuromonitoring, WISE is also active in the field of neuromodulation, developing its WISEneuro\xc2\xae Modulation product family.